Latest news : Mabpharm Limited

06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI
27/12/24	Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection)	CI

More news

Press Releases: Mabpharm Limited

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

More press releases

Managers and Directors: Mabpharm Limited

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

More insiders

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

389

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	HK$0.3950	-5.95%	152,000
02/07/26	HK$0.4200	0.00%	0
30/06/26	HK$0.4200	0.00%	30,000
29/06/26	HK$0.4200	0.00%	0
26/06/26	HK$0.4200	-4.55%	554,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. Other stock markets 11:08:15 03/07/2026 +03			5-day change	1st Jan Change
0.3950 ^HKD	-5.95%		-5.95%	-21.00%

Market Cap	1.41B 1.63B 208M 182M 167M 156M 295M 19.78B 299M 2B 779M 9.72B 780M 763M 33.5B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.63B 1.88B 240M 210M 193M 180M 341M 22.83B 346M 2.31B 899M 11.22B 900M 881M 38.66B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

1 day	-5.95%
1 week	-5.95%
Current month	-5.95%
1 month	-5.95%
3 months	-21.00%
6 months	-21.00%
Current year	-21.00%

1 week	0.36	0.42
1 month	0.31	0.45
Current year	0.31	0.81
1 year	0.31	0.88
3 years	0.25	0.94
5 years	0.25	1.4
10 years	0.25	1.8

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	-5.95%	-5.95%	-21.00%	-29.46%	208M
ARGENX SE	+0.68%	+5.92%	+77.86%	+139.22%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+91.40%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+43.36%	-4.67%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-28.41%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+361.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+37.85%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
Average	+1.99%	+7.11%	+46.72%	+127.75%	24.57B
Weighted average by Cap.	+2.46%	+6.46%	+58.26%	+136.83%

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news : Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Course Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	258M 298M 38.04M 33.26M 30.56M 28.49M 54.04M 3.62B 54.85M 367M 143M 1.78B 143M 140M 6.14B	646M 747M 95.19M 83.21M 76.47M 71.28M 135M 9.06B 137M 918M 357M 4.45B 357M 350M 15.35B
Net income	-128M -148M -18.85M -16.48M -15.14M -14.12M -26.77M -1.79B -27.18M -182M -70.68M -882M -70.75M -69.24M -3.04B	57.13M 66.02M 8.42M 7.36M 6.76M 6.3M 11.96M 801M 12.14M 81.18M 31.56M 394M 31.59M 30.92M 1.36B
Net Debt	222M 257M 32.74M 28.62M 26.31M 24.52M 46.51M 3.12B 47.21M 316M 123M 1.53B 123M 120M 5.28B	217M 251M 32.04M 28.01M 25.74M 23.99M 45.51M 3.05B 46.2M 309M 120M 1.5B 120M 118M 5.17B